MediLink ADC Beats Topotecan in China SCLC Trial With NDA Under Review
Interim results from the China-only TAISHAN-302 phase III trial show MediLink's Tam-Peli extended median overall survival to 13.3 months versus 9.4 months for topotecan in relapsed small-cell lung cancer, with a hazard ratio of 0.46. China's drug regulator has accepted the New Drug Application and proposed priority review, though this does not constitute marketing approval. The findings apply only to the 451-patient Chinese trial population; global phase III trials are planned but have not yet started or produced results.